Could delirium and anti-dementia drugs effect on the treatment of agitated nursing home residents with Alzheimer dementia?

In a recent issue of Journal of the American Medical Directors Association, Viscogliosi et  al have achieved important results in testing safer and more effective alternatives in the treatment of agitation in nursing home residents with Alzheimer dementia (AD).1 There is insufficient data on the comparison of citalopram with antipsychotics in this regard, indicating that this study could make important contributions for beneficial treatment options in agitation improvement in AD patients. Besides, the authors may not have considered a few factors that could affect the results in the adjusted analysis.
Source: Journal of the American Medical Directors Association - Category: Health Management Authors: Tags: Letter to the Editor Source Type: research

Related Links:

Early-onset dementia and Alzheimer ’s disease jumped 200% among commercially insured Americans between the ages of 30 and 64 over a recent five-year period, a new analysis of Blue Cross and Blue Shield health insurer claims shows.
Source: Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
(NIH/National Institute on Aging) NIH will host the National Research Summit on Care, Services and Supports for Persons with Dementia and Their Caregivers. The event will offer reporters a chance to hear from renowned experts on a wide range of topics, including Alzheimer's disease, which is the most common form of dementia.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
Population health has been around for decades, but it is now taking center stage in Alzheimer ’s disease (AD) and dementia care. The Centers for Disease Control and Prevention (CDC) are encouraging and empowering these efforts with a Public Health Approach to Alzheimer’s Disease and Dementia curriculum. “This is an important strategy,” said Arif Nazir, MD, FACP, AGSF, CMD, Signature HealthCARE chief medical officer and president of AMDA – The Society for Post-Acute and Long-Term Care Medicine. “We have millions of patients with dementia, and these numbers will increase.
Source: Caring for the Ages - Category: Health Management Authors: Source Type: news
Authors: Lee YM, Park SH, Lee DH Abstract OBJECTIVE: The aim of this paper is to propose a new hypothesis for the role of lipophilic chemical mixtures stored in adipose tissue in the development of dementia. Specifically, we present how the dynamics of these chemicals can explain the unexpected findings from the Action for Health in Diabetes (Look AHEAD) study, which failed to show long-term benefits of intentional weight loss on cognition, despite substantial improvements in many known risk factors for dementia. Moreover, we discuss how the role of obesity in the risk of dementia can change depending on the dynami...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: Buee L Abstract Tau is a microtubule-associated tau proteins but it has also non-microtubular functions. It aggregates in Alzheimer's disease and many neurodegenerative disorders referred to as tauopathies. Such aggregation may result from mutations on the tau gene, MAPT, dysregulation in alternative splicing, post-translational modifications or truncation. This final chapter addresses some of the various researches on a therapeutic potential around the tau protein and its gene, MAPT. Many therapeutic strategies are ongoing but they are hampered by the lack of knowledge on tau physiological funct...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Experimental Models of Tauopathy - From Mechanisms to Therapies. Adv Exp Med Biol. 2019;1184:381-391 Authors: Götz JJ, Götz J Abstract Animal models have been instrumental in reproducing key aspects of human tauopathy. In pursuing these efforts, the mouse continues to have a prominent role. In this chapter, we focus on models that overexpress wild-type or mutant forms of tau, the latter being based on mutations found in familial cases of frontotemporal dementia. We review some of these models in more detail and discuss what they have revealed about the underlying pathomechanisms, as well...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Watanabe H, Bagarinao E, Yokoi T, Yamaguchi H, Ishigaki S, Mausuda M, Katsuno M, Sobue G Abstract Misfolded and aggregated tau and amyloid β (Aβ) proteins are the pathological hallmarks of Alzheimer's disease (AD). These aberrant proteins lose their physiological roles, acquire neurotoxicity, and propagate across neural systems. Despite the growing understanding of the molecular pathophysiology, the relationship among molecular alterations, pathological changes, and dementia onset and progression remain to be elucidated. Connectivity is an exclusive characteristic of the brain, and the integrity ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. Adv Exp Med Biol. 2019;1184:187-203 Authors: Gallardo G, Holtzman DM Abstract Alzheimer's disease (AD) is the most common form of dementia characterized neuropathologically by senile plaques and neurofibrillary tangles (NFTs). Early breakthroughs in AD research led to the discovery of amyloid-β as the major component of senile plaques and tau protein as the major component of NFTs. Shortly following the identification of the amyloid-β (Aβ) peptide was the discovery that a genetic mutation in the amyloid precursor prote...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Associations Between APOE Variants, Tau and α-Synuclein. Adv Exp Med Biol. 2019;1184:177-186 Authors: Rodriguez-Vieitez E, Nielsen HM Abstract Neurodegenerative diseases are characterized by the aggregation and deposition of misfolded proteins in the brain, most prominently amyloid-β (Aβ), tau and α-synuclein (α-syn), and are thus referred to as proteinopathies. While tau is a hallmark of Alzheimer's disease (AD) and other non-AD tauopathies, and α-synuclein is the pathological feature of the spectrum of synucleinopathies including Parkinson's disease (PD), Parkinson's...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Hanger DP, Goniotaki D, Noble W Abstract The microtubule-associated protein tau has been identified in several intraneuronal compartments, including in association with synapses. In Alzheimer's disease, frontotemporal dementia and related tauopathies, highly phosphorylated tau accumulates as intraneuronal protein aggregates that are likely responsible for the demise of neurons and the subsequent progressive cognitive decline. However, the molecular mechanisms underlying such tau-mediated damage in the tauopathies is not fully understood. Tauopathy induces loss of synapses, which is one of the earliest stru...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Alzheimer's | Celexa | Citalopram | Dementia | Health Management | Nurses | Nursing | Study